Violeta Dinesch, Mihail Dinesch, Ileana Voichita Sirbu, Cosmin Macarie, Bogdan Vasile Halatiu and Mircea Buruian
1. Bønaa K, Mannsverk J, Wiseth R, et al. - Drug-eluting or bare-metal stents for coronary artery disease. N Engl J Med. 2016;375:1242-1252.
2. Kaneko H, Yajima J, Oikawa Y, et al. - Long-term incidence and prognostic factors of progression of new coronary lesions in Japanese coronary artery disease patients after percutaneous coronary intervention. Heart Vessels. 2014;29:437-442.
3. Park MW, Seung KB, Kim PJ, et al. - Long-term percutaneous coronary intervention rates and associated independent
Sonja Stojanović, Bojana Stamenković, Jovan Nedović, Tatjana Jevtović-Stoimenov and Dušica Pavlović
4. Angwin J, Heald G, Lloyd A, Howland K, Davy M and James MF. Reliability and sensitivity of Joint Space Measurements in Hand Radiographs Using Computerized Image Analysis. J Rheumatol 2001; 28:1825-36.
5. Larsen A. How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long-term studies. J Rheumatol 1995; 22:1974-5.
6. Van Tuyl LHD, Voskuyl AE, Boers M, Geusens P, Landewé RMB, Dijkmans BAC et al. Baseline RANKL: OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in
Desislava M. Bozhkova and Elena G. Poryazova-Markova
1. Boyer B, Thiery J. Epithelium-mesenchyme interconversion as example of epithelial plasticity. Apmis 1993; 101: 257-68.
2. D’Souza-Schorey C. Disassembling adherens junctions: breaking up is hard to do. Trends Cell Biol 2005; 15: 19-26.
3. Hugo H, Ackland M, Blick T. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 2007; 213: 374-83.
4. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004; 118: 277-9.
5. Thiery J
Ivan Jovanovic, Nevena Gajovic, Gordana Radosavljevic, Jelena Pantic, Nada Pejnovic, Nebojsa Arsenijevic and Miodrag L. Lukic
R, McFarland AP, Reynolds DA et al. A novel role for IL-22R1 as a driver of inflammation. Blood 2011; 117: 575-84.
61. Park O, Wang H, Weng H et al. In vivo consequences of liver-specific interleukin-22 expression in mice: implications for human liver disease progression. Hepatology 2011; 54: 252-61.
62. Riccardi C, Santoni A, Barlozzari T, Puccetti P, Herberman RB. In vivo natural reactivity of mice against tumour cells. Int J Cancer 1980; 25: 475-486.
63. Wiltrout RH, Herberman RB, Zhang SR et al. Role of organ-associated NK cells in decreased
Vasil G. Marinov, Desislava N. Koleva-Georgieva, Nelly P. Sivkova and Maya B. Krasteva
DK, Schmid CH, et al. Cumulative illness severity and progression from moderate to severe retinopathy of prematurity. Journal of Perinatology 2007;27:502-9.
15. Akkoyun I, Oto S, Yilmaz G, et al. Risk factors in development of mild and severe retinopathy of prematurity. J AAPOS 2006;10:449-53.
16. Yang MB, Donovan EF, Wagge JR. Race, gender, and clinical risk index for babies (CRIB) score as predictors of severe retinopathy of prematurity. J AAPOS 2006;10:253-61.
17. Karna P, Muttineni J, Angel L, et al. Retinopathy
Nenad Markovic, Ana Lukovic, Nebojsa Arsenijevic, Srdjan Ninkovic and Biljana Ljujic
transition as a source for carcinoma-associated fibroblasts. Cancer Res. 2007;67(21):10123-8.
10. D’souza N, Burns JS, Grisendi G, Candini O, Veronesi E, Piccinno S, Horwitz EM, Paolucci P, Conte P, Dominici M. MSC and Tumors: Homing, Differentiation, and Secretion Influence Therapeutic Potential. Adv Biochem Eng Biotechnol. 2013;130:209-66.
11. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010;1805(1):105-17.
12. Place AE et al. The microenvironment in breast cancer progression
Katalin Csép, Eszter Szigeti and Krisztina Szalman
Objective: Methylene-tetrahydrofolate reductase (MTHFR) is involved in adapting metabolism to environmental challenges by various mechanisms, including the control of gene expression by epigenetic and post-translational changes of transcription factors. Though a metabolic syndrome candidate gene, association studies of its common polymorphism rs1801133 (MTHFR-Ala222Val) remain inconclusive with important ethnic differences, and the effect on disease progression was not addressed.
Methods: 307 middle-aged metabolic syndrome patients in a central Romanian hospital setting were investigated metabolically, and genotyped by PCR-RFLP. Disease progression was assessed by the age of onset of metabolic components, as well as development of non-alcoholic fatty liver disease and atherosclerotic complications.
Results: The minor allele frequency of rs1801133 was 30.13%. Metabolic parameters showed no statistically significant differences according to genotype, but variant carriers developed dysglycemia and dyslipidemia earlier (53.28±10.8 vs 59.44±9.31 years, p<0.05 and 58.57±11.31 vs 64.72±10.6 years, p<0.1).While the polymorphism did not influence hepatic complications, an inverse association was found for manifest atherosclerosis (OR=0.49, p=0.006, 95%CI:0.29-0.81), which may be folate-status dependent, and needs further investigations. Simultaneous analysis with transcription factor polymorphisms (rs1801282, rs8192678) showed that the more protective genotypes were present the later metabolic disturbances developed, and in the presence of the other two variants the apparent protective cardiovascular effect disappeared.
Conclusions: The common functional polymorphism rs1801133 may influence metabolic syndrome progression, the age of onset of components and development of atherosclerotic complications. Besides simple additive effects, complex mitigating and aggravating variant interactions may exist, and the protective or predisposing outcome may depend on modifiable environmental factors.
, Choi BT, Lee YT, Park DI, Rhee SH, Park KY, et al. Resveratrol inhibits cell proliferation and induces apoptosis of human breast carcinoma MCF-7 cells. Oncol Rep. 2004; 11:441-6.
11. Park JW, Choi YJ, Jang MA, Lee YS, Jun DY, Suh SI, et al. Chemopreventive agent resveratrol, a natural product derived from grapes, reversibly inhibits progression through S and G2 phases of the cell cycle in U 937 cells. Cancer Lett. 2001; 163:43-9.
12. Roncoroni L, Elli L, Dolfini E, Erba E, Dogliotti E, Terrani C, et al. Resveratrol inhibits cell growth
Sofija Pejkova, Gjorgje Dzokic, Smilja Tudzarova-Gjorgova and Sasho Panov
, Kumasaka MY, Thang ND et al. RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signali ng in Malignant Melanoma Progression and Therapy. Dermatol Res Pract. 2012; 2012: 354191.
21. Nogueira C, Kim KH, Sung H et al. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene. 2010; 29(47): 6222–32.
22. Scatolini M, Grand MM, Grosso E et al. Altered molecular pathways in melanocytic lesions. Int J Cancer. 2010; 126(8): 1869–81.
23. Jakob JA, Bassett RL Jr, Ng CS et al. NRAS mutation status is an independent prognostic factor in
Locally advanced gastric cancer with a high risk of intraperitoneal progression is characterized by poor prognosis. After radical surgery, most patients die during the first two years post-operation as a result of disease progression. The prevailing type of progression and the leading cause of death in patients with gastric cancer is implantation metastasis.
The main risk factors for peritoneal carcinomatosis in such patients include: gastric tumor invasion into serosa, the presence of tumor cells in peritoneal washings, the largeness of the tumor as accompanied by extensive serous lesions, infiltrative type of tumor growth, histological variants of gastric cancer prone to implantation metastasis and metastatic lesions in regional lymph nodes. Systemic chemotherapy does not provide effective eradication of subclinical peritoneal carcinomatosis in patients with locally advanced gastric cancer.
The vast majority of patients who suffer from locally advanced gastric cancer and run a high risk of implantation metastasis are characterized by subclinical peritoneal dissemination at primary diagnosis, which means a rapidly fatal prognosis for such patients. In recent years, however, the paradigm of treatment of locally advanced gastric cancer has changed: a combination of surgery and adjuvant hyperthermic intraperitoneal chemotherapy is used increasingly, and presents an alternative to the previously accepted surgery only approach. It is also likely to increase the survival rate.